Table 1

Baseline characteristics of the 107 patients with axial spondyloarthritis who received adalimumab with or without MTX (n=107)

P value
Sex, male22 (42)28 (51)0.48
HLA B27-positive30 (58)33 (60)0.78
Age (years)43(18-71)41(18-65)0.61
BMI (kg/m2)25(18-35)27(17-40)0.24
Disease duration (years)3 (0–34)2 (0–41)0.93
Previous TNF inhibitor12 (23)8 (15)0.38
ASDAS3.0 (1.0–5.4)3.2 (1.5–5.0)0.70
CRP level (mg/L)2.5 (0–65)4 (0–57)0.50
  • Data are median (range) or n (%).

  • ASDAS, Ankylosing Spondylitis Disease Activity Score; BMI, body mass index; CRP, C-reactive protein; HLA, human leukocyte antigen; MTX, methotrexate; MTX−, adalimumab alone; MTX+, methotrexate+adalimumab; TNF, tumour necrosis factor.